\
&
Contact us
\
&
Contact us
AP Hogeschool Antwerpen - research@ap.be - 03/220 56 49
Arteveldehogeschool Gent - EU-research@arteveldehs.be - 09/234 91 68 or 09/234 91 16
Flanders Make - Ger van den Kerkhof - 011/ 79 05 60
Hogeschool Gent - onderzoek@hogent.be - 09/243 32 84
ILVO - Cathy Plasman - 09/272 25 31
IMEC - Anne.vandenbosch@imec.be - 016/281 682
INBO - evinbo@inbo.be - 0490/ 66 68 76
Instituut voor Tropische Geneeskunde - research@itg.be - 03/247 66 86
KU Leuven Idea>proposal - Eu-info@kuleuven.be - 016/320 944-446
KU Leuven Proposal>Project - Lrd.eu@kuleuven.be - 016/320 631-621
LUCA School of Arts - matthias.somers@luca-arts.be - 02/447 18 42
Odisee vzw - Willem vanden Berg - 09/267 27 14
UCLL - Research.expertise@ucll.be - 011/180 900
Universiteit Antwerpen - research@uantwerpen.be - 03/265 30 02
Universiteit Gent - EU-team@ugent.be - 09/264 3029
Universiteit Hasselt - Euresearch@uhasselt.be - 011/268050 - 9043
VIB - Lieve.ongena@vib.be - 09/244 66 11
VITO - EU-liaison@vito.be - 014/335 669
VIVES Hogeschool - Elke Denys - 056/28 06 29
Vrije Universiteit Brussel - elo@vub.be - 02/629 2210
Throughout Flanders, several Flemish institutes offer support services for European funding for research and innovation, also known as the European Liaison offices.
The list here is non-exhaustive and being continuously updated. In case your institute would like to be included on this page please send a message to info@ncpflanders.be.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
